Compare CCHH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | SNGX |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.2M |
| IPO Year | N/A | 2006 |
| Metric | CCHH | SNGX |
|---|---|---|
| Price | $0.66 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.2M | 164.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.00 |
| 52 Week High | $15.39 | $6.23 |
| Indicator | CCHH | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 44.92 |
| Support Level | $0.62 | $1.01 |
| Resistance Level | $0.68 | $1.47 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 26.55 | 45.31 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).